

Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in Renal Cell Carcinoma – Tweetorial #1

Reference List

1. SEER. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. National Cancer Institute. Bethesda, MD. Accessed October 6, 2021. <https://seer.cancer.gov/statfacts/html/kidrp.html>
2. SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed October 7, 2021. <https://seer.cancer.gov/explorer/>
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Kidney Cancer (v2.2022). Updated September 8, 2021. Accessed September 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
4. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol*. 2009;27(34):5794-9. doi:10.1200/JCO.2008.21.4809
5. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*. 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079.
6. Ljungberg B, Albiges L, Bedke J, et al. EAU Guidelines on Renal Cell Carcinoma. *European Association of Urology*. 2021.
7. Powles T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. *Ann Oncol*. 2021;doi:10.1016/j.annonc.2021.09.014
8. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol*. 2020;31(8):1030-1039. doi:10.1016/j.annonc.2020.04.010.
9. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2021;384(9):829-841. doi:10.1056/NEJMoa2026982
10. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med*. 2021;384(14):1289-1300. doi:10.1056/NEJMoa2035716.
11. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2020;21(12):1563-1573. doi:10.1016/s1470-2045(20)30436-8.

12. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. *J Clin Oncol*. 2021;39(15_suppl):4500-4500. doi:10.1200/JCO.2021.39.15_suppl.4500.
13. Choueiri TK, Powles T, Porta C, et al. A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study). Presented at: Kidney Cancer Research Summit; 2021; Philadelphia, PA, USA. Accessed October 19, 2021. <https://kcrs.kidneycan.org/wp-content/uploads/2021/10/Abstracts-Book-KCRS-2021-v2-10112021.pdf>
14. Motzer RJ, Tannir NM, McDermott DF, et al. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *Ann Oncol*. 2021;32:S685-S687. doi:10.1016/j.annonc.2021.08.057.
15. Lee C-H, Shah AY, Hsieh JJ, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). *J Clin Oncol*. 2020;38(15_suppl):5008-5008. doi:10.1200/JCO.2020.38.15_suppl.5008.
16. ClinicalTrials.gov. Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors. NCT02501096. Updated June 14, 2021. Accessed October 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT02501096>
17. Albiges L, Barthelemy P, Gross-Goupil M, Negrier S, Needle MN, Escudier B. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. *Ann Oncol*. 2021;32(1):97-102. doi:10.1016/j.annonc.2020.09.021.
18. ClinicalTrials.gov. Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC. NCT03136627. Updated July 12, 2021. Accessed October 5, 2021. <https://clinicaltrials.gov/ct2/show/NCT03136627>
19. ClinicalTrials.gov. Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma. NCT04987203. Updated October 7, 2021. Accessed October 26, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04987203?term=tivozanib&cond=Renal+Cell+Carcinoma&phase=2&draw=2&rank=1>
20. Pal SK, Albiges L, Suarez Rodriguez C, et al. CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma. *J Clin Oncol*. 2021;39(6_suppl):TPS370-TPS370. doi:10.1200/JCO.2021.39.6_suppl.TPS370.
21. ClinicalTrials.gov. A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune

Checkpoint Inhibitor Treatment (CONTACT-03). NCT04338269. Updated August 18, 2021.
Accessed September 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04338269>